TherapeuticsMD (TXMD) Accumulated Expenses (2011 - 2026)

TherapeuticsMD has reported Accumulated Expenses for 15 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 1627.91% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 1627.91% YoY), and the FY2025 full-year result was $1.7 million, down 18.15% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.2 million, up from $1.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $3.1 million in Q4 2023, with the low at $129000.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $1.9 million across 4 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 32.11% — and 2026, when it surged 1627.91%.
• TherapeuticsMD's Accumulated Expenses stood at $3.1 million in 2023, then sank by 32.11% to $2.1 million in 2024, then dropped by 18.15% to $1.7 million in 2025, then advanced by 28.03% to $2.2 million in 2026.
• The last three Accumulated Expenses figures came in at $2.2 million (Q1 2026), $1.7 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.